Stock REGN REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-02 pm EDT 		5-day change 1st Jan Change
1,045 USD -1.17% Intraday chart for Regeneron Pharmaceuticals, Inc. -2.48% +18.94%
Jul. 02 Regeneron Pharmaceuticals Insider Sold Shares Worth $1,190,564, According to a Recent SEC Filing MT
Jun. 28 Regeneron Gets European Health Agency Committee's Positive Opinion for Conditional Marketing Authorization of Lymphoma Drug Candidate Odronextamab MT

Evolution of the average Target Price on Regeneron Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

786d2502a0c1.q0vwtIogqoRqtXIVzgFxBKXlBc_LY28_NuXhvtgfd_8.knig8eFq791b2B8hoHsyPZemNYv6UldYQIi4yrB9L5D6JpnlzlHozB7qKw~5b309ed9eb32557487abbf22809f63ac

Analyst Recommendations on Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Insider Sold Shares Worth $1,190,564, According to a Recent SEC Filing MT
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,170 From $1,060, Buy Rating Maintained MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,596,400, According to a Recent SEC Filing MT
JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $1,150 From $1,050 MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $25,610,229, According to a Recent SEC Filing MT
Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $1,125 From $1,050 MT
RBC Capital Raises Price Target on Regeneron Pharmaceuticals to $1,229 From $1,200, Maintains Outperform Rating MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $798,821, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing MT
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,185 MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115 MT
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25 MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $48,636,545, According to a Recent SEC Filing MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,115 From $1,060 MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $35,207,110, According to a Recent SEC Filing MT
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept MT
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126 MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177 MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016 MT
RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189 MT
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,057 USD
Average target price
1,051 USD
Spread / Average Target
-0.53%
High Price Target
1,229 USD
Spread / Highest target
+16.27%
Low Price Target
720 USD
Spread / Lowest Target
-31.88%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Regeneron Pharmaceuticals, Inc.

JPMorgan Chase
Wells Fargo Securities
RBC Capital Markets
Jefferies & Co.
Piper Sandler
UBS
Deutsche Bank Securities
Goldman Sachs
Morgan Stanley
Oppenheimer
TD Cowen
Cantor Fitzgerald
Truist Securities
Canaccord Genuity
Barclays
BMO Capital
Baird
BofA Securities
Raymond James
WestPark Capital
Guggenheim
SVB Securities LLC
EF Hutton
Cowen
Evercore ISI
Argus
Bernstein
Benchmark Capital
HC Wainwright
SVB Leerink
Credit Suisse

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. Consensus Regeneron Pharmaceuticals, Inc.